Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland
Bristol-Myers Squibb
Bristol-Myers Squibb
Novartis
Novartis
University of Chicago
Akeso
Abramson Cancer Center at Penn Medicine
National Cancer Institute (NCI)
Fundación GECP
Syndax Pharmaceuticals
University of Michigan Rogel Cancer Center
Sun Yat-sen University
Hospices Civils de Lyon
Institut Bergonié
Changhai Hospital
University Medical Centre Maribor
M.D. Anderson Cancer Center
Insel Gruppe AG, University Hospital Bern
Changhai Hospital
Memorial Sloan Kettering Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Fudan University
Shandong First Medical University
Arab American University (Palestine)
Shanghai Junshi Bioscience Co., Ltd.
Helwan University
Incyte Corporation
Mansoura University
The First Affiliated Hospital with Nanjing Medical University
University of Virginia
Zhejiang University
Sun Yat-sen University
MacroGenics
Fujian Medical University
Azienda Ospedaliero-Universitaria di Modena
University Hospital, Antwerp
Cordgenics, LLC
Regeneron Pharmaceuticals
AGO Research GmbH
Regeneron Pharmaceuticals
The Netherlands Cancer Institute
Hunan Province Tumor Hospital
University of Colorado, Denver
BPGbio
Alliance for Clinical Trials in Oncology
Gruppo Italiano Malattie EMatologiche dell'Adulto
Mario Negri Institute for Pharmacological Research
AstraZeneca
Taproot Health
AstraZeneca
University of California, San Francisco